Amgen, Inc v. Connecticut Retirement Plans & Trust Funds (U.S. Supreme Court)

Connecticut Retirement Plans and Trust Funds filed a securities-fraud complaint against Amgen, alleging Amgen made certain misrepresentations to the FDA during the approval process for a drug later marketed by Amgen. The issue before the Supreme Court was whether, as a prerequisite for class certification, the plaintiffs had to prove that Amgen’s alleged misrepresentations were material. We represented several former SEC Commissioners and law professors as amicus curiae at the certiorari stage, and successfully urged the Supreme Court to grant review. We also represented the former SEC Commissioners law professors as amicus curiae at the merits stage, urging the Court to reverse the decision of the Court of Appeals.